March 22, 2017 / 12:17 PM / 5 months ago

BRIEF-OPKO receives FDA orphan drug status to treat genetic neurological disorder

March 22 (Reuters) - OPKO Health Inc-

* OPKO receives FDA orphan drug status for its new oligonucleotide to treat genetic neurological disorder

* OPKO Health Inc says OPKO plans to initiate a clinical trial of cur-1916 for treatment of dravet syndrome this year

* Received orphan drug designation from U.S. FDA for oligonucleotide-based antagonat (cur-1916) for treatment of dravet syndrome Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below